M. Carpentieri

3.1k total citations
12 papers, 242 citations indexed

About

M. Carpentieri is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Carpentieri has authored 12 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Carpentieri's work include TGF-β signaling in diseases (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Heterotopic Ossification and Related Conditions (2 papers). M. Carpentieri is often cited by papers focused on TGF-β signaling in diseases (4 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Heterotopic Ossification and Related Conditions (2 papers). M. Carpentieri collaborates with scholars based in Italy, United States and South Korea. M. Carpentieri's co-authors include Carla Caccia, Alessandro Rossi, G. Di Chiara, Antonello Abbattista, Cristina Noberasco, Filippo de Braud, Jordan Berlin, Stephen Jones, Raghunadharao Digumarti and Hossein Borghaei and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

M. Carpentieri

11 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Carpentieri Italy 7 92 87 70 58 36 12 242
Rosa Queralt Spain 12 33 0.4× 157 1.8× 24 0.3× 36 0.6× 36 1.0× 14 338
Anna Petroccione Italy 6 20 0.2× 85 1.0× 77 1.1× 26 0.4× 16 0.4× 13 233
Krzysztof Sadowski Poland 11 36 0.4× 106 1.2× 72 1.0× 34 0.6× 7 0.2× 17 330
Xiaolong Sui China 7 32 0.3× 164 1.9× 38 0.5× 16 0.3× 38 1.1× 17 258
Amy Gerrish United Kingdom 10 46 0.5× 112 1.3× 54 0.8× 20 0.3× 7 0.2× 18 289
Emily Pham United States 5 83 0.9× 104 1.2× 47 0.7× 12 0.2× 12 0.3× 7 228
B. A. Oostra Netherlands 7 49 0.5× 123 1.4× 18 0.3× 179 3.1× 12 0.3× 10 382
Chuncheng Xie China 9 41 0.4× 133 1.5× 28 0.4× 15 0.3× 18 0.5× 11 246
William Wu United States 8 30 0.3× 134 1.5× 35 0.5× 14 0.2× 14 0.4× 12 273
Mae-Jean Miller United States 6 130 1.4× 228 2.6× 93 1.3× 11 0.2× 9 0.3× 8 373

Countries citing papers authored by M. Carpentieri

Since Specialization
Citations

This map shows the geographic impact of M. Carpentieri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Carpentieri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Carpentieri more than expected).

Fields of papers citing papers by M. Carpentieri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Carpentieri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Carpentieri. The network helps show where M. Carpentieri may publish in the future.

Co-authorship network of co-authors of M. Carpentieri

This figure shows the co-authorship network connecting the top 25 collaborators of M. Carpentieri. A scholar is included among the top collaborators of M. Carpentieri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Carpentieri. M. Carpentieri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Shaw, Alice T., Todd M. Bauer, Toshiaki Takahashi, et al.. (2018). P1.13-06 First-Line Lorlatinib Versus Crizotinib for Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S584–S584. 5 indexed citations
2.
3.
Simonelli, Matteo, Paolo Andrea Zucali, Armando Santoro, et al.. (2016). Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Annals of Oncology. 27(9). 1782–1787. 31 indexed citations
4.
Goff, Laura W., Roger B. Cohen, Jordan Berlin, et al.. (2015). A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(9). 2146–2154. 26 indexed citations
5.
Simonelli, Matteo, Crystal S. Denlinger, Laura W. Goff, et al.. (2014). Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control.. Journal of Clinical Oncology. 32(15_suppl). 4095–4095. 2 indexed citations
6.
Simonelli, Matteo, Paolo Andrea Zucali, Melanie B. Thomas, et al.. (2013). Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 31(15_suppl). 4121–4121. 7 indexed citations
7.
Kern, K. A., M. Carpentieri, Mark R. Middleton, et al.. (2011). Absolute bioavailability of PF-01367338 tablets following oral administration in cancer patients.. Journal of Clinical Oncology. 29(15_suppl). e13615–e13615. 1 indexed citations
8.
Dirix, Luc, Jorge Ignacio, Shona Nag, et al.. (2008). Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. Journal of Clinical Oncology. 26(8). 1253–1259. 45 indexed citations
9.
Breda, Massimo, et al.. (1992). A STUDY OF THE EFFECTS OF RIFABUTIN ON ISONIAZID PHARMACOKINETICS AND METABOLISM IN HEALTHY VOLUNTEERS. Drug metabolism and drug interactions. 10(4). 323–340. 12 indexed citations
10.
Moretti, Antonio, Nicola Carfagna, Carla Caccia, & M. Carpentieri. (1989). Effect of ergolines on neurotransmitter systems in the rat brain.. PubMed. 294. 33–45. 14 indexed citations
11.
Caccia, Carla, G. Achilli, M. Carpentieri, et al.. (1988). Receptor Adaptive Responsiveness in Disease Models: 6-Ohda Lesioned and Spontaneously Hypertensive Rats. Journal of Receptor Research. 8(1-4). 97–105. 3 indexed citations
12.
Caccia, Carla, et al.. (1986). D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. European Journal of Pharmacology. 126(3). 347–348. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosa Queralt Breakdown of academic impact, for papers by Anna Petroccione Breakdown of academic impact, for papers by Krzysztof Sadowski Breakdown of academic impact, for papers by Xiaolong Sui Breakdown of academic impact, for papers by Amy Gerrish Breakdown of academic impact, for papers by Emily Pham Breakdown of academic impact, for papers by B. A. Oostra Breakdown of academic impact, for papers by Chuncheng Xie Breakdown of academic impact, for papers by William Wu Breakdown of academic impact, for papers by Mae-Jean Miller
Rankless by CCL
2026